Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive News 3 Undervalued Names Too Cheap to IgnoreSubmitted by Nathan Reiff. Published: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Highly publicized growth trajectories of some of the biggest companies out there may make 2026 seem like a poor time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below are potential value plays, with valuation metrics that are historically low or competitive relative to peers or the broader market. They also offer added benefits—such as attractive dividends or promising new product developments. Although value opportunities can be harder to find when many names have already regained investor attention (and some apparent bargains have deteriorating fundamentals), well-established and stable names can still represent compelling value. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Although shares have risen more than 28% over the past year, lifting biopharma giant Merck & Co. Inc. (NYSE: MRK) to a market capitalization near $300 billion, the stock still trades at a price-to-earnings (P/E) ratio of 16.45—well below the medical-industry average of about 27. Analysts project earnings growth of nearly 10% next year and see roughly 5% additional upside in the near term. Keytruda, Merck's pembrolizumab cancer drug, continues to drive momentum. It was approved for subcutaneous injection by the European Commission in late 2025 and generated about $8.4 billion in sales in Q4 2025, up nearly 7% year over year. Keytruda also shows promise in ovarian cancer, potentially expanding its patient base—trends that should help Merck sustain revenue as Keytruda approaches patent expiration in 2028. Merck's pipeline is broadening as well: the company recently announced phase 3 trial results for clesrovimab-cfor (Enflonsia), an RSV treatment for young children. At the same time, Merck is reorganizing its human health division into two units to make it easier to grow non–cancer-drug sales ahead of Keytruda's loss of exclusivity. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) shares have dropped roughly 37% over the past year as the food-and-beverage company faces pressure from tariffs and inflation. In Q1 fiscal 2026 (ended Nov. 2, 2025), organic net sales and consumption declined modestly year over year, while adjusted earnings per share fell 13%. The company has yet to realize meaningful margin improvement from its cost-saving initiatives, and near-term guidance remains weak. Still, Campbell's benefits from improving supply-chain operations and strong brand loyalty—especially for its premium offerings—which should help protect results as tariff pressures shift. It also remains an attractive dividend play, offering a 5.9% yield, though the payout ratio is over 80%. With a P/E of about 13.5—the lowest in roughly four years—Campbell's may appeal to value-oriented investors despite Wall Street caution. A Recent US Foods Rally May Continue; Bottom-Line Growth Remains in Place Foodservice-distribution leader US Foods (NYSE: USFD) has taken almost the opposite path of Campbell's, with shares climbing roughly 33% over the past year. Its P/E of 31.6 remains reasonable for a company transitioning toward stronger profitability. US Foods reported improving profitability in the latest quarter and full-year adjusted EBITDA rose about 11% year over year. Better inventory management and cost-of-goods savings are helping the company gain traction. With a $4 billion capital deployment plan, US Foods is positioned to sustain revenue momentum and continued adjusted-EBITDA growth. Analysts rate USFD a Moderate Buy (11 Buys, 2 Holds) with roughly 15% upside potential.
| 
